A state of the art review on the novel mediator asprosin in the metabolic syndrome

Carla Luís, MD\textsuperscript{a,b,*}, Rúben Fernandes\textsuperscript{b,c}, Raquel Soares\textsuperscript{a,b}, Pedro von Hafe\textsuperscript{d,e}

Abstract

Metabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this syndrome like: obesity, inflammation, hypertension, insulin resistance, atherosclerotic dyslipidemias, endothelial dysfunction, and inflammation. This circuit is intermediated by a complex network of hormones, cytokines, transcription factors, and adipokines, among others. Some like leptin, adiponectin, Plasminogen activator inhibitor-1, interleukin-6, Tumor necrosis factor, and their influence on the metabolic syndrome are well described in the literature and new players are described continuously. One novel player was described in 2016 by Romere et al as a fasting-induced glycogenic protein hormone named asprosin.

In order to perform a state-of-the-art, nonsystematic review of asprosin, a study of the available literature was carried out in the main database (Pubmed) and the results were studied and correlated to better understand the mechanism of action of this hormone. Asprosin is not only associated with the metabolic syndrome features like glucose and lipid metabolism, insulin resistance, obesity and inflammation but also in other pathologies metabolic syndrome related like diabetic retinopathy, polycystic ovary syndrome and anorexia nervosa. A limited number of pathways were already unveiled although much more research is needed to better understand the therapeutical potential of asprosin in the metabolic syndrome.

Keywords: asprosin, diabetes, inflammation, metabolic syndrome, metabolism, obesity

Introduction to metabolic syndrome

The Metabolic Syndrome (MetS) was first described by the Swedish physician Kylin in 1923 as a concept rather than a diagnosis. It stood for the association between hypertension, hyperglycemia, and gout.\textsuperscript{1} The evolution of MetS integrated new features over time and was identified with different designations. The combination of obesity in the MetS was termed as “insulin-resistance syndrome,” “Syndrome X” assembled insulin-stimulated glucose uptake, hypertension, type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD),\textsuperscript{3} and “deadly quartet” brought together obesity, glucose intolerance, hypertriglyceridemia, and hypertension.\textsuperscript{4}

Asprosin, a novel mediator

One recent player in the metabolic game is asprosin. Asprosin is a fasting-induced protein hormone secreted by the adipose tissue and recruited by the liver.\textsuperscript{9} Protein hormones are a subclass of hormones that usually use a cell-surface receptor to bind to the target cell, using a secondary messaging system they stimulate rapid signal transduction. Most of protein hormones result from

As an extremely complex and heterogeneous pathology (Fig. 1), there are many controversies regarding the most accurate definition for MetS by different academic societies (Table 1). Regardless of cutoffs of criteria, most agree that MetS is a cluster of biochemical, physiologic metabolic features which lead to higher levels of mortality due to risk factors like diabetes and impaired glucose metabolism, insulin resistance, abdominal obesity, impaired lipid metabolism, and high blood pressure.\textsuperscript{5}

Obesity (abdominal obesity in particular) and insulin resistance are the core of MetS, as adipose tissue releases a panoply of local and systemic bioactive molecules like adipokines, cytokines, and transcription factors that results on increased insulin resistance, lipolysis of triglycerides, and increased free fatty acids (FFA)\textsuperscript{6} (Fig. 2).

Moreover, the infiltration of immune cells in the adipose tissue promotes the state of chronic low-grade inflammation mediated by proinflammatory molecules (TNF-\alpha and IL-6) and acute-phase proteins (CRP and PAI-1) increasing inflammatory signaling via the downstream activation of pathways like NFkB and JNK, resulting in an inhibition of the insulin signaling.\textsuperscript{7} In addition, adipokines (adiponectin and leptin) are insulin modulators by the maintenance of the energy balance and several peripheral metabolic mechanisms responsible for food intake, energy expenditure, and other neuroendocrine functions.\textsuperscript{8}
the cleavage of larger proteins; asprosin is the result of the C-terminal cleavage product of profibrillin (encoded by FBN1) and exemplifies a glucogenic protein hormone. It was first described in Neonatal Progeroid Syndrome (NPS), which is associated with FBN1 truncating mutations which results in the ablation of asprosin. Ablation of asprosin is accountable for a distinctive symptom of NPS: subcutaneous lipoatrophy.9

Asprosin circulating levels are increased by fasting as a response to the low plasma glucose concentrations. In the liver, it binds to a G-protein-coupled receptor—later known to be OLF73410 and activates the G protein-cAMP-PKA pathway resulting in the secretion of hepatic glucose9 (Fig. 3).

**Observational studies of asprosin in glucose and lipid metabolism**

Romere et al9 unveil the mechanism behind the glucose and lipid metabolic dysfunction but no studies succeed to fully understand
if asprosin is the result of a protective feedback mechanism or the result of metabolic disorders. Nonetheless, evidence between glucose and lipid metabolism was shown in several observational studies.

The research by Wang et al recruited 143 Chinese subjects and divided them into three groups: normal glucose regulation (NGR, \( n = 52 \)), impaired glucose regulation (IGR, \( n = 40 \)), and newly diagnosed type 2 diabetes (nT2DM group, \( n = 51 \)). Results show that plasma asprosin levels were significantly higher in IGR and nT2DM individuals and correlated with various clinical parameters of glucose and lipid metabolic disorders. The authors found a positive correlation with waist circumference (WC), fasting plasma glucose (FPG), post challenge plasma glucose (2hPG), glycated hemoglobin (HbA1c), triglyceride (TG), and homeostasis model assessment for insulin resistance (HOMA-IR). In addition, a negative correlation was found with homeostasis model assessment for \( \beta \)-pancreatic cell function (HOMA-\( \beta \)), area under the curve of the first-phase (0–10 min) insulin secretion (AUC), acute insulin response (AIR), and glucose disposition index (GDI). Combination of all parameters analyzed delineated a typical diabetic profile, where asprosin seems to play an important role and be a potential biomarker in T2DM and consequently in MetS.

Matching results were obtained by Zhang et al regarding individuals with NGR and nT2DM, serum asprosin concentrations were significantly increased in the nT2DM group \(^{12}\) and positively correlated with adiposity-related parameters like body mass index (BMI), WC and waist-hip ration (WHR) and also with TG. \(^{13}\)

**Asprosin and obesity management**

Obesity is one of the main features in MetS, and already considered a growing epidemic and a public health problem. One target organ in the management of adiposity is the central nervous system: the response of hypothalamus to neurotransmitters released by the gastrointestinal tract plays a key role in energy homeostasis and appetite control. \(^{14}\)

Appetite control is a complex neurometabolic network of physiology pathways in response to fasting hormones. Duersschmid et al demonstrated that asprosin is able to cross the blood–brain barrier (BBB) and activate the hypothalamic feeding system and provoke appetite stimulation. \(^{15}\) The hypothalamus system responsible for appetite control consists on the regulation of NPY/AgRP \(^{+}\) (orexigenic) and POMC/CART (Anorexigenic) neurons. The experiments carry by Duersschmid et al in mice model observed that asprosin, not only activated AgRP+ neurons, (only \( \sim 50\% \) were asprosin responsive by cells which contain the components necessary for transducing the asprosin-dependent signal) via a G-protein, adenylate cyclase, cAMP, and PKA pathway, but also inhibited \( \sim 85\% \) of the POMC+ neurons. \(^{16}\) The balance resulted in appetite stimulation \(^{16}\) (Fig. 4).

This correlation is also supported by other studies. Ugur et al found a clear evidence that asprosin concentration increases in accordance with BMI, the method was performed both in blood and saliva and disclose that salivary glands also synthesize asprosin. \(^{17}\) This study revealed an advantage of using asprosin as a biomarker for it will be possible to obtain a non-invasive
sample. Moreover, asprosin levels decreased significantly after bariatric surgery associated with the decrease of BMI.\textsuperscript{18}

Research performed in children reveal controversial results. While Silistre et al as well as Wang et al obtained higher levels of asprosin in children with obesity\textsuperscript{19,20} as expected, Long et al observed a decrease in asprosin levels in children with obesity when compared with the normal weight control group, but no elucidation was given for these results.\textsuperscript{21}

Interestingly enough, in anorexia nervosa (AN), a psychiatric disorder characterized by self-induced weight loss and appetite deregulation, the levels of asprosin were also increased and correlated with interoceptive awareness. The authors of this work postulate that the abnormal interaction between asprosin and insula is the responsible link; insula plays an important role in some of the symptoms of AN.\textsuperscript{22}

Asprosin and inflammation

As it was described previously, inflammation is also a key regulation in MetS due to the inflammatory cytokines and acute phase proteins produced in the adipocytes. Lee et al reported that asprosin also contributes to inflammation, cellular dysfunction, and apoptosis in pancreatic β-cells and human primary islets.\textsuperscript{23} In this study, it was performed cellular assays with recombinant asprosin in MIN6 cells and human primary islets. The results reveal increased inflammation state, impaired glucose-stimulated insulin secretion, and promotion of apoptosis. These results suggests that not only adipocytes but also pancreatic β-cells can produce asprosin, furthermore, asprosin presented to be a novel ligand of toll-like receptor 4 (TLR4) that will promote inflammation and β-cell dysfunction by activation of JNK pathway\textsuperscript{23} (Fig. 5).

In addition, FFA can promote endoplasmic reticulum (ER) stress which, by various inflammatory signals, will lead to augmented insulin signaling therefore to insulin resistance.\textsuperscript{24} Jung et al evaluated the effect of asprosin treatment in muscle cells: differentiated C2C12 myocytes and isolated mouse soleus skeletal muscle.\textsuperscript{25} They demonstrated that asprosin treatment resulted on elevated ER stress biomarkers (IRE-1—inositol-requiring enzyme 1; eIF2α—eukaryotic initiation factor 2α; CHOP—C/EBP homologous protein) that led to PKCδ activation and nuclear translocation, decreased SERCA activity and concluded on the impairment of insulin sensitivity in skeletal muscle by an unknown receptor\textsuperscript{25} (Fig. 6).

Asprosin in pathologies—metabolic syndrome related

The correlation between asprosin and pathologies directly associated with MetS such as obesity, insulin impairment, T2DM, and inflammation has been subject of several studies in the scientific community. Other pathologies were also contemplated and asprosin correlated that are somewhat MetS associated like polycystic ovary syndrome (PCOS).
A research performed by Ko et al aim to study the influence of aerobic exercise on asprosin levels in type 1 diabetes mellitus (T1DM). Their results show that in streptozotocin-induced T1DM mouse model, the levels of asprosin was increased when compared to the non-diabetic control and that aerobic exercise decreased asprosin levels via PKA/TGF-β to control levels approximately.26

Other studies also associated increased plasma levels of asprosin in gestational diabetes mellitus (GDM). In a prospective study named early diagnosis of gestational diabetes mellitus (EDoGDM), a case-control of 40 pregnant women with GDM and 40 control cases with normal glucose tolerance (NGT) was performed to evaluate the levels of asprosin. Asprosin was higher in plasma of GDM as early as 18–20 gestational weeks and present in their offspring. The authors also observed asprosin expression in placenta from both groups.27 Moreover, a study performed by Baykus et al observed similar results, although asprosin levels were increased not only in GDM, but also in preeclampsia, severe preeclampsia and macrosomic fetuses, other interesting and unsolved result obtained was in intrauterine growth retardation where the levels of asprosin were significantly decrease.28

Regarding diabetic complications, diabetic retinopathy (DRP) is characterized by an increased edema and angiogenesis in the retina due to hyperglycemia. A quantification of blood and aqueous humor asprosin was performed in 30 patients with DRP and cataract, 30 patients with diabetes mellitus and cataract without DRP and 30 healthy controls. The results observed a significant increase in patients with DRP. The authors suggest that these findings could be a clinical tool to establish risk of DRP development.29

Also, an association was already observed between diabetes and chronic viral hepatitis as an additional risk factor,30 but no evidence has been shown in asprosin levels.31

On the subject of cardiovascular diseases, a study was performed by Chen et al reveal that asprosin can improve microvascular endothelium damage in the diabetic heart of mice through upregulation of the spartin/ROS signaling pathway.32 Another work from Zhang et al demonstrated that asprosin pretreatment of mesenchymal stromal cells (MSCs) and transplantation to the heart of mice that suffered myocardial infarction results in an improvement of cardiac health. Asprosin-pretreated MSCs are more resistant to apoptosis induced by both oxidative stress in vitro and myocardial ischemia in vivo, by activation of the ERK1/2 signaling pathway which upregulates antioxidant proteins (SOD2). SOD 2 will promote the decrease of Reactive Oxygen Species (ROS) and inhibit apoptosis.33 Moreover, asprosin levels can predict the severity of acute coronary syndrome in unstable angina pectoris.34

Polycystic ovary syndrome (PCOS) is a metabolic disorder in which insulin resistance plays a vital role. It is characterized by hyperandrogenism and/or hirsutism. Two studies demonstrated that asprosin levels are elevated in women with POCD. One demonstrated a positive correlation with insulin resistance, BMI, and free androgen index (FAI).35 The other a positive correlation with fasting blood glucose (FBG), hemoglobin A1c (HbA1c), LDL-c, APOB, APOE, testosterone and HOMA.36

Discussion and conclusions
The majority of the studies included in this review reveal increase levels of asprosin in pathologies associated with the metabolic syndrome. Still, few researchers had found decreased levels especially in obesity-related syndromes in children. A common consensus is needed to improve the knowledge of asprosin underlying mechanisms in order to uncover its potential as a
diagnostic and/or therapeutical target. Research already recognized that anti-asprosin monoclonal antibodies can reduce blood glucose, decrease appetite therefore body weight and could be considered as a diabetic and obesogenic therapy.\(^{37}\) One promising therapeutical drug is a peripheral cannabinoid receptor 1 (CB1R) antagonism AM6545 which was able to lower the asprosin levels. In a monosodium glutamate (MSG)-induced obesity mice model characterized by abdominal obesity, dyslipidemia and insulin resistance, the treatment with AM6545 reduce not only asprosin levels but also others circulating adipokines including leptin with a positive metabolic improvement.\(^{38}\)

Obesity and diabetes are the fundamental core of MetS and there’s still no efficient therapy to either of these conditions. Asprosin disclosures not only an association with these pathologies but also with other diseases involved in MetS. Asprosin appears as a promising therapeutical target in MetS but there is still a hard road ahead. A better understanding of asprosin could bring new insights and reveal asprosin as the fundamental link between MetS risk factors.

**Conflicts of interest**

The author declares that there are no conflicts of interest.

**References**

[1] E K. Studien ueber das Hypertonie-Hyperglyca “mie- Hyperurika” miesyndrom. Zentralblatt fuer Inn Medizin. 1923;1:105–127.

[2] Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9:452–459.

[3] Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.

[4] Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514–1520.

[5] Cornier M-A, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29:777–822.

[6] Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428.

[7] Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–355.

[8] Nawrocki AR, Scherer PE. The delicate balance between fat and muscle: Adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol. 2004;4:281–289.

[9] Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566–579.

[10] Li E, Shan H, Chen L, et al. OLRF734 Mediates Glucose Metabolism as a Receptor of Asprosin. Cell Metab. 2019;30:319–328.e8.

[11] Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflam. 2018;2018:1–7.

[12] Zhang X, Jiang H, Ma X, Wu H. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Invest. 2020;11:349–355.

[13] Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–188.

[14] Makaronidis JM, Batterham RL. The role of gut hormones in the pathogenesis and management of obesity. Current Opinion in Physiology. 2019;12:1–11.
Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444–1453.

Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel player in metabolic diseases. Front Endocrinol. 2020;11:1–7.

Uğur K, Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol. 2019;2019:1–8.

Wang CY, Lin TA, Liu KH, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes. 2019;43:1019–1025.

Wang M, Yin C, Wang L, et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2020;75:205–212.

Sünetçi Silistre E, Hatipoğlu HU. Increased serum circulating asprosin levels in children with obesity. Pediatr Int. 2020;62:467–476.

Long W, Xie X, Du C, et al. Decreased circulating levels of asprosin in obese children. Horm Res Paediatr. 2019;91:271–277.

Hu Y, Xu Y, Zheng Y, et al. Increased plasma asprosin levels in patients with drug-naive anorexia nervosa. Eat Weight Disord. 2020;Epub ahead of print.

Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900–917.

Jung TW, Kim HC, Kim HU, et al. Asprosin attenuates insulin signaling pathway through PKC-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234:20888–20899.

Zhong L, Long Y, Wang S, et al. Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study. Placenta. 2020;93:17–22.

Baykus Y, Yavuzkir S, Üstebay S, Uğur K, Deniz R, Aydin S. Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preclampsia, severe preeclampsia, intrauterine growth retardation and macrosomic fetus. Peptides. 2019;120:1–5.

Orcu Y, Celik F, Ozgur G, et al. Altered blood and aqueous humor levels of asprosin, 4-hydroxynonenal, and 8-hydroxy-deoxyguanosine in patients with diabetes mellitus and cataract with and without diabetic retinopathy. Retina. 2020;Epub ahead of print.

Mason AL, Lau JYN, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328–333.

Eser Karlidag G, Arslan Solmaz O. Are adiprin, apelin, elabela, asprosin and betatrophin biomarkers for chronic hepatitis and staging of fibrosis? Biotech Histochem. 2020;95:152–159.

Chen S, Wang X, Qiu CM, et al. Study of the role and mechanism of asprosin/spartin pathway in cardiac microvascular endothelial injury induced by diabetes mellitus. Sichuan da xue xue bao Yi xue ban = Sichuan Univ Med Sci Ed. 2019;50:827–834.

Zhang Z, Tan Y, Zhu L, et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci. 2019;231:1–12.

Acara AC, Bolatkal M, Kızılıoglu I, Ibişoglu E, Can Ç. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin. Am J Emerg Med. 2018;36:1504–1505.

Alan M, Gurlek B, Yılmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35:220–223.

Li X, Liao M, Shen R, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm. 2018;9:1–11.

Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes. 2020;69:559–566.

Ma H, Zhang G, Mou C, Fu X, Chen Y. Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Front Pharmacol. 2018;9:1–10.